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Treatment of cytomegalovirus (CMV) disease in solid organ transplant (SOT) recipients has been shown to reduce the risk of death, allograft damage, and length of hospitalization [1] [2] [3] . In addition to the resolution of clinical symptoms, the efficacy of antiviral therapy is guided by CMV diagnostic testing, which is most commonly with the use of quantitative nucleic acid testing (QNAT) [4] .
Three viral load measures have been demonstrated to correlate with the clinical outcome of CMV disease treatment. First, a relationship between pretreatment CMV load and resolution of CMV disease has been proposed. Transplant patients with a baseline viral load higher than the threshold of 10 000 copies/mL (in one study [5] ) or 20 000 copies/mL (in another study [6] ) had significantly longer time to resolution of CMV disease compared to those with lower viral loads. Second, the rate of CMV load decline during antiviral treatment has been significantly correlated with treatment outcomes [7] . And third, studies have demonstrated the importance of viral suppression as a guide to treatment responses [8, 9] . In this regard, guidelines recommend the attainment of viral load suppression as a measure of a successful CMV disease treatment.
Despite the suggested roles of viral load monitoring in CMV disease treatment, there is a lack of well-defined viral load thresholds to guide clinicians in the management of SOT patients. This unmet clinical need is due to the lack of standardization and reproducibility of results of the various QNAT assays. Until recently, there was no international reference standard for calibration of CMV QNAT assays, which has prevented the establishment of broadly applicable cutoffs for clinical decision making [10] [11] [12] . The First World Health Organization (WHO) International Standard for Human Cytomegalovirus for Nucleic Acid Amplification Techniques, NIBSC code 09/162 (CMV WHO Standard), was released for standardization of QNAT tests in 2010. Once adopted, this makes it possible to create standardized guidelines with clear thresholds for diagnosing and managing CMV infection and disease across various viral load technologies. Regulatory authorities and professional organizations will likely require clinical laboratories and manufacturers to standardize CMV QNAT tests and report the results in international units (ie, IU/mL) rather than copies per milliliter.
To date, there have been no clinical studies that have been performed using assays calibrated to this international standard. Hence, to better understand the virologic goals of antiviral therapy in SOT patients with CMV disease, we performed a retrospective clinical study of a CMV load test standardized against the CMV WHO Standard in which results were correlated to clinical resolution of CMV disease. The influence on outcome was investigated for 2 viral monitoring prediction rules: (1) suppression of viremia (below the viral load test reporting range) during monitoring timepoints and (2) specific changes in viral titers over time. In addition, the utility of pretreatment CMV load and differences in viral load among patients with CMV syndrome vs tissue-invasive CMV disease were assessed.
METHODS

Study Population
This study retested plasma samples from the VICTOR Study [5] , which was an international randomized controlled trial that compared the efficacy of intravenous ganciclovir (5 mg/kg every 12 hours, adjusted based on renal function) vs oral valganciclovir (900 mg twice daily, adjusted based on renal function) for 21 days followed by oral valganciclovir (900 mg once daily, adjusted based on renal function) maintenance therapy for an additional 28 days in SOT patients with CMV disease. The study followed International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use guidelines on the ethical conduct of research. Each study participant signed an informed consent form, and the study was approved by an independent institutional review board prior to its conduct.
Clinical Follow-up, Definitions, and Study Outcome
In the original VICTOR Study, the following clinical data were collected at study entry (baseline): CMV load measured by local assays, demographics, CMV serologic status, physical exam findings, biopsy/tissue sample findings, immunosuppressive regimen, and any prior anti-CMV therapy (whether prophylactic, preemptive, or for treatment of CMV disease). Regular clinical assessments for CMV disease activity were performed in the VICTOR Study at baseline ( pretreatment) and on study days 3, 7, 10, 14, 17, 21, 28, 35, 42, and 49. SOT patients were classified as having tissue-invasive CMV disease if clinical evidence of end-organ damage or CMV in biopsy specimens were present. CMV syndrome was defined as the presence of CMV in the blood with fever, leukopenia, malaise, or thrombocytopenia. In the current study, the primary clinical outcome measure was the time to CMV disease resolution, and this was defined by the number of days from baseline to the clinical resolution of CMV disease.
Viral Load Testing
Stored ethylenediaminetetraacetic acid plasma specimens were retested using a novel assay, COBAS AmpliPrep/COBAS TaqMan CMV Test (TaqMan CMV Test; Roche Molecular Diagnostics [RMD], Branchburg, New Jersey), at baseline and treatment days 7, 14, 21, 28, and 49. Samples with sufficient volume for testing were eligible for inclusion.
Viral load values were expressed in international units (IU/ mL) based on the test's calibration to the CMV WHO Standard. The conversion factor between CMV DNA copies (as determined by the TaqMan CMV Test) and international units (IU) is 1.1 copies/IU (0.91 IU/copies) for the TaqMan CMV Test [13] . The standards used during development of the TaqMan CMV Test were the CMV WHO Standard, an RMD CMV Secondary Standard, and the Source Material for the Secondary Standard that was a CMV cultured virus type AD169, and an RMD CMV Calibration Panel using a Lambda CMA1.2. The aforementioned standards, the CMV Calibration Panel, and an independent CMV clinical specimen were diluted to similar levels and then tested to validate the test's accuracy to the CMV WHO Standard. Table 1 shows the accuracy of the test and its secondary standards and calibrators to the CMV WHO Standard. The test demonstrated accuracy when testing all materials within 0.3 log 10 IU/mL, a specification based upon laboratory input and consensus. All materials also demonstrated co-linear dilution performance across the linear range of the TaqMan CMV Test, as published elsewhere [14] .
Statistical Analysis
The primary outcome measure (time to resolution of CMV disease after the initiation of antiviral treatment) was assessed for association with (1) pretreatment viral load results, (2) viral load declines of 1.0, 1.5, 2.0, and 2.5 log 10 IU/mL from baseline to days 7, 14, and 21 of treatment, and (3) viral load suppression at various timepoints.
For pretreatment viral load, results were dichotomized at 18 200 (4.26 log 10 ) IU/mL, based on published data on the clinical relevance of 20 000 copies/mL [6] and taking the test's conversion factor into account. Viral suppression below the TaqMan CMV Test's lower limit of quantification (LLOQ) included results that were detected but below the LLOQ (<137 IU/mL or <2.14 log 10 IU/mL) and results that were undetectable. Viral load suppression was assessed at days 7, 14, and 21, and was analyzed in relation to the time to resolution of CMV disease. Patients with pretreatment viral loads that were below the LLOQ were excluded from analyses of change in or suppression of viral load. Kaplan-Meier survival plots were used for univariate assessment of the differences between the time (in days) to clinical resolution of CMV. Censoring information, estimates of median time to resolution (with 95% confidence intervals [CIs]), the log-rank test statistic and associated P value, and the hazard ratio (HR) from a univariate Cox proportional hazards model were calculated for each Kaplan-Meier survival plot. Multivariate Cox proportional hazards models were used to examine the relationship between the time to resolution of CMV disease and the viral load suppression outcomes by days 7, 14, and 21 while adjusting for relevant baseline covariates. For categorical covariates (eg, organ recipient CMV serostatus), adjusted hazard ratios (AHRs) were calculated. Where hazard ratios are shown, the category denoted by (1.00) is the reference, and AHR values >1.00 indicate a shorter time to disease resolution, whereas AHR values <1.00 indicate a longer time to disease resolution. Analyses examining the association between viral load monitoring for tissue-invasive CMV disease and CMV syndrome were also performed. Statistical analyses were performed using the SAS statistical package (SAS Institute, Cary, North Carolina).
RESULTS
Patient Characteristics
Of 321 VICTOR Study participants, 267 (83.2%) had sufficient plasma volume at each of the timepoints of interest to be eligible for enrollment in the current study. Demographic and clinical characteristics of the VICTOR Study have been previously published [5] , and there were no significant differences between the subset of participants in the current study and the original study population (data not shown).
Viral Load Summary
In total, 1522 plasma samples were tested. At baseline, 11.7% of participants had viral loads that were detected below the assay reporting range of 137 (2.14 log 10 ) IU/mL. The mean baseline viral load was 5129 (3.71 log 10 ) IU/mL for those with viral load results within the assay reporting range. No results were above the upper limit of quantification (9.1 × 10 6 IU/mL or 6.96 log 10 IU/mL). During the course of antiviral treatment, the proportion of the study population with CMV suppression increased at days 7, 14, 21, 28, and 49 to 22.4%, 35.0%, 59.4%, 74.2%, and 88.1%, respectively. The mean viral load among those with quantifiable results declined progressively from baseline Bolded rows indicate statistically significant correlations (P < .05).
Abbreviations: AHR, adjusted hazard ratio; CAP/CTM, COBAS AmpliPrep/COBAS TaqMan CMV Test; CI, confidence interval, CMV, cytomegalovirus. a Rows with hazard ratio estimates within parentheses (1.00) indicate reference categories.
b Reference category was "not on cyclosporine A, T-cell suppressors, or corticosteroids."
through to day 49 as follows: 5129 (3.71 log 10 ), 1585 (3.2 log 10 ), 537 (2.73 log 10 ), 62 (1.79 log 10 ), 20 (1.31 log 10 ), and 10 (1.01 log 10 ) IU/mL at the respective days of monitoring. Figure 1A shows the Kaplan-Meier curves for CMV disease resolution based on pretreatment viral loads above and below the predefined cutoff of 18 200 (4.26 log 10 ) IU/mL. The plot shows clear separation of the curves early in the course of treatment, indicating that patients with a lower pretreatment viral load resolve CMV disease more rapidly than those with a higher viral load. The median time to clinical resolution is 5 days longer for those with higher viral load (12 days vs 7 days; HR, 1.51; log-rank test, P = .002). In multivariable analysis that adjusted for age, race/ethnicity, recipient CMV serostatus, prior anti-CMV therapy, and immunosuppressive regimen, the association between lower baseline viral load and shorter time to CMV disease resolution remained statistically significant with an AHR of 1.56 (P = .001; Table 2 ). In addition, younger patient age (18-29 years), black race, and CMV seropositivity were significantly associated with more rapid clinical disease resolution, whereas Asian race was associated with a more protracted clinical recovery. Figure 1 shows the Kaplan-Meier plots for CMV disease resolution for SOT patients with or without viral load suppression at days 7, 14, and 21 of treatment. Those with viral suppression below the LLOQ of the TaqMan CMV Test had significantly faster time to disease resolution compared to those with viral load values >137 (2.14 log 10 ) IU/mL. At days 7, 14, and 21, SOT patients who remained with detectable virus (ie, >137 IU/mL or >2.14 log 10 IU/mL) had 5, 5, and 7 days, respectively, longer time to resolve clinical disease (HRs ranged from 1.48 to 1.70; P values ranging from <.001 to .009). These associations between viral suppression and time to clinical resolution remained significant after adjusting for potential Bolded rows indicate statistically significant correlations (P < .05).
Association Between Pretreatment Viral Load and CMV Disease Resolution
Association of Viral Load Suppression and CMV Disease Resolution
Abbreviations: AHR, adjusted hazard ratio; CI, confidence interval; CMV, cytomegalovirus; LLOQ, lower limit of quantification. a Row hazard ratio estimates within parentheses as (1.00) indicate reference categories.
confounders (Table 3 ). The 95% CIs that did not cross 1.00 (Table 3) indicated that the AHRs were significant at or below a P value of .05. Other factors that were significantly associated with time to CMV disease resolution in the multivariable model include younger age, black race, and recipient CMV seropositivity, whereas Asian race was associated with slower clinical resolution.
Lack of Significant Association Between Viral Decline and CMV Disease Resolution
The multivariable Cox proportional hazards models to test for the association between viral load decline at days 7, 14, and 21 with time to clinical CMV disease resolution showed no significant correlations. At day 7, the AHRs ranged from 0.82 to 1.37 for the viral decline rules of 1.0-2.5 log 10 IU/mL from baseline, but all P values for the differences were >.3. At day 14 and day 21, similar AHR and nonsignificant P values were found.
Clinical Resolution of CMV Syndrome vs Tissue-Invasive CMV Disease
The mean baseline viral load of participants with CMV syndrome was 9120 (3.96 log 10 ) IU/mL and for those with tissueinvasive CMV was 20 893 (4.32 log 10 ) IU/mL. Figure 2 shows the Kaplan-Meier plot comparing clinical resolution based on CMV disease category. SOT patients with tissue-invasive CMV disease had a median of 6 days longer time to clinically resolve CMV disease compared to CMV syndrome (Figure 2 ). Significant association between pretreatment viral load and clinical disease resolution was observed for both CMV syndrome and tissue-invasive CMV disease ( Table 4 ). The significance of the associations between viral suppression and a shorter time to clinical resolution was maintained for both CMV syndrome and tissue-invasive CMV disease, with the exception of day 7 for CMV syndrome (Table 4) .
DISCUSSION
Clinical practice guidelines recommend viral load monitoring to guide the treatment of transplant patients with CMV disease [4] . The lack of assay standardization, until recently, has limited the generation of viral thresholds that can be applied for various clinical applications. Herein we report the first study correlating clinical outcomes of CMV disease treatment with viral load, as measured by a novel assay that has been standardized and calibrated to the CMV WHO Standard. This study emphasized the clinical importance of (1) viral load at the start of treatment ( pretreatment viral load), and (2) viral load at the end of treatment (viral suppression) as 2 viral measures that are significantly associated with faster time Figure 2 . Kaplan-Meier survival plot of time to resolution of cytomegalovirus (CMV) disease by CMV disease type. Open squares and triangles represent right-censored data. One participant's CMV disease category could not be classified and was excluded from this analysis. Abbreviation: CMV, cytomegalovirus. to clinical disease resolution. In contrast, the degree of viral decline from baseline was not significantly correlated with time to resolution of clinical disease. Although these viral load measures have previously been reported as important surrogates of clinical responses [8, 9, 15] , the novelty of this study is the use of an assay that has been calibrated to the international standard, and reporting in international units. This will therefore facilitate the direct comparison of viral load measures across centers and studies, with the eventual aim of generating clinically meaningful thresholds for various clinical applications. Equally as important, this study provides solid data to indicate that the use of pretreatment viral load and viral suppression during weekly monitoring as a guide to clinical disease resolution was similar for CMV syndrome and tissue-invasive CMV disease. Previous studies have combined both diseases in a single analysis, but the large number of patients in this study has allowed us to perform separate analysis.
The association between pretreatment viral load and viral suppression as correlates to time to clinical disease resolution was significant even after adjustment for various variables such as CMV serostatus, age, and race/ethnicity. The cohort was heterogenous in terms of CMV prevention strategy after transplantation. Approximately half of the patients were managed posttransplant with a preemptive CMV strategy, but the applicability of baseline and monitoring viral load rules did not seem to be affected by prior anti-CMV therapy. Indeed, the applicability of the findings to patients with active CMV disease appeared to be robust across the many potential confounders measured in this study.
Several strengths of this study need to be emphasized. First, the study was conducted in a large cohort of kidney, liver, pancreas, heart and lung transplant recipients. Second, there were sufficient numbers of CMV syndrome and tissue-invasive disease, and the analysis indicated that the 2 viral load measures were equally useful for monitoring both types of CMV disease. Third, although this is a post hoc study, the clinical follow-up was performed prospectively using standardized protocols, thereby limiting the risk of bias that is inherent of retrospective studies. Fourth, the assessment of CMV disease clinical resolution was performed by clinicians blinded to the CMV load measurements. The definition of CMV disease resolution in this study was based solely upon clinical assessment and did not include an assessment of the TaqMan CMV Test result in the blood as a prerequisite for the determination of resolution.
Limitations of this study include the exclusion of severe and life-threatening cases of CMV disease. Hence, the clinical relevance of these viral load measures may not be applicable to this group of patients with severe CMV disease. This study also was aimed at assessing the viral load in CMV disease resolution, and did not address the other potential applications of standardized viral load monitoring. Specifically, the utility of viral load in predicting the risk of CMV disease (and late onset CMV disease after prophylaxis) and as guide for preemptive therapy were not assessed. The study was also performed in plasma samples, and thus, we recommend other studies to also assess viral load in other blood compartments and body fluids. There was a predominance of kidney transplant recipients, and the majority of patients were CMV seropositive prior to transplantation. Nonetheless, the significance of pretreatment viral load and viral load suppression remained after adjusting for recipient CMV serostatus, suggesting that potential wide applicability of these measures in both highrisk and moderate-risk patients.
In conclusion, this study is the first to correlate CMV disease resolution during antiviral therapy with standardized viral load measures. As more laboratories calibrate their viral load tests to the CMV WHO Standard, consensus across transplant centers on when to start and stop treatment will be facilitated by common reporting. With the availability of a standard, we encourage the performance of clinical studies to determine viral load thresholds for predicting of CMV disease risk and for guiding preemptive therapy.
Notes
